Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates
Most viewed

From the Editors

Lerodalcibep: What does LIBerate-HeFH tell us?

Prof Derick RaalProfessor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.

Read the editorial


Related content:

LIBerate-HeFH: Lerodalcibep reduces LDL-C in HeFH

In Case You Missed It

Derrick Raal
PCSK9 inhibition with a novel fusion protein

Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, presents efficacy and safety data from Phase 3 trials of lerodalcibep.

Christie Ballantyne
Oral PCSK9 inhibition: Clinical update

Christie Ballantyne, Baylor College of Medicine, Houston, USA, reports Phase 2b results with the oral PCSK9 inhibitor, MK-0616.

News from ACC 2024

ACC 2024 View ACC.24 reports »

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower LDL-C, which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature CV death and disability.
Read more »

Increasing awareness, knowledge and understanding of elevated serum TGs in the development of CVD and pancreatitis and stimulating research of novel therapeutic strategies.


Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the Sorbonne University Prof Henry GinsbergIrving Professor of Medicine, Columbia University Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology